Macrophage-Amphiregulin Axis Mediates Myofibroblast Transition in S. aureus Osteomyelitis

Study Background and Research Question

Osteomyelitis, a persistent inflammation of bone usually caused by bacterial infection, poses a significant challenge in both trauma and orthopedic care. Epidemiological analyses reveal that the risk of posttraumatic osteomyelitis can range from 2.16% in minor open fractures to upwards of 59% in severe cases, with Staphylococcus aureus (S. aureus) accounting for 26.3–44.4% of infections (reference). Despite aggressive antibiotic regimens, recurrence rates remain high, partially due to the formation of deep bone abscesses that hinder effective drug delivery and immune response. Although the cellular composition of S. aureus abscesses has been catalogued, the mechanisms driving persistent infection and antibiotic failure are not fully understood.

Key Innovation from the Reference Study

Yang et al. (2025) identify a previously uncharacterized regulatory axis in the bone marrow: macrophage-derived amphiregulin (AREG) signals to adiponectin-positive (Adipoq+) marrow adipogenic lineage precursors (MALPs), inducing their transition into myofibroblasts. This phenotypic switch provokes local vascular constriction, impairs blood perfusion, and restricts antibiotic access to infected sites, thereby facilitating persistent S. aureus colonization (reference). The authors further pinpoint the AREG/EGFR/mTOR/YAP signaling axis as a critical driver of this process, offering a new antifibrotic therapeutic target.

Methods and Experimental Design Insights

The study employs a multifaceted approach integrating advanced genetic, pharmacological, and imaging tools:

• Genetically engineered mouse models were used to track Adipoq+ cell fate and selectively ablate macrophage AREG or EGFR in Adipoq+ cells.
• Implant-associated S. aureus osteomyelitis was induced to mimic clinical bone infection, with blood perfusion monitored using intravital imaging in Cdh5CretdTomato mice.
• Pharmacological inhibition of EGFR and mTOR was tested to assess the impact on myofibroblast formation and bacterial clearance.
• Histology, immunofluorescence, and single-cell RNA sequencing provided spatial and molecular resolution of cellular transitions and pathway activation.

Core Findings and Why They Matter

The principal discoveries can be distilled as follows:

• Adipoq+ precursors are mobilized to the periphery of S. aureus abscesses and undergo myofibroblast transition, a process rarely associated with adipogenic lineage cells in the context of infection (reference).
• Myofibroblast formation leads to local vascular constriction, reducing blood flow, impeding immune cell access, and limiting antibiotic penetration to the abscess core.
• Macrophage-derived amphiregulin (AREG) is essential for this transition: deleting AREG in macrophages or EGFR in Adipoq+ cells, or inhibiting EGFR/mTOR pharmacologically, significantly reduced fibrosis, restored perfusion, and improved bacterial clearance.
• Targeted interventions against the AREG/EGFR/mTOR/YAP pathway decreased myofibroblast numbers, enhanced antibiotic delivery, and reduced S. aureus burden in bone (reference).

These findings position the macrophage-Adipoq+ axis as a fundamental regulator of abscess persistence in osteomyelitis and suggest that antifibrotic strategies can potentiate standard antibiotic therapy.

Comparison with Existing Internal Articles

Several internal resources focus on the utility of potent anti-inflammatory compounds, such as QNZ (EVP4593), for dissecting complex cellular pathways involved in infection, inflammation, and tissue remodeling:

• QNZ (EVP4593): Elite NF-κB Inhibitor for Inflammation Models describes applications of QNZ in models of macrophage-driven fibrosis and its reproducibility in NF-κB pathway modulation, directly relevant to studies like Yang et al. where inflammatory signaling underpins pathological fibrosis (workflow_recommendation).
• Precision NF-κB Pathway Modulation: Strategic Guidance for Inflammation Research explores the mechanistic basis for using nanomolar NF-κB inhibitors in both inflammatory and neurodegenerative disease models, providing protocol insights transferable to osteomyelitis research where NF-κB activation is implicated (workflow_recommendation).

These articles expand on how chemical inhibitors like QNZ (EVP4593) can be used to interrogate the molecular crosstalk between immune cells and stromal populations—a central theme in the reference paper.

Protocol Parameters

• NF-κB pathway inhibition (cell-based assay) | 11 nM IC50 | Jurkat T cells, inflammation models | Enables high-sensitivity modulation of inflammatory signaling relevant to macrophage-driven fibrosis | product_spec
• Inhibition of TNF-α production (cellular assay) | 7 nM IC50 | Anti-inflammatory compound screening | Reflects compound potency for suppressing pro-inflammatory cytokine release | product_spec
• In vivo anti-inflammatory efficacy (rat paw edema) | Significant edema reduction | Preclinical inflammation models | Demonstrates translation of pathway inhibition to tissue-level anti-inflammatory effects | product_spec
• Neurodegenerative disease model (SOC influx in neurons) | Attenuates calcium entry | Huntington’s disease research | Shows applicability to models of chronic inflammation and neurodegeneration | product_spec
• Solubility (DMSO) | ≥15.05 mg/mL | Cell-based and in vivo workflows | Supports preparation of concentrated stock solutions for experimental flexibility | product_spec

Limitations and Transferability

While the study provides compelling evidence that targeting the AREG/EGFR/mTOR/YAP axis can break the cycle of fibrosis and impaired drug delivery in osteomyelitis, several limitations remain:

• The findings are grounded in murine models with genetically tractable systems; human bone marrow biology and immune responses may introduce additional complexity (reference).
• Pharmacological inhibitors used in the study are not always directly translatable to clinical protocols; further preclinical validation is needed.
• Potential off-target effects of EGFR/mTOR inhibition in other marrow or stromal lineages were not exhaustively explored.

Transferability to other chronic infection or fibrotic settings is plausible but should be empirically validated.

Research Support Resources

Researchers investigating NF-κB signaling and stromal-immune interactions in infection or fibrosis can leverage well-characterized inhibitors to dissect pathway contributions. QNZ (EVP4593) (SKU A4217), supplied by APExBIO, is a potent quinazoline derivative NF-κB inhibitor validated in both in vitro and in vivo models of inflammation and neurodegeneration (workflow_recommendation). For detailed guidance on protocol optimization, see comparative studies and scenario-driven recommendations in internal articles. This approach supports high-sensitivity, reproducible modulation of inflammatory pathways relevant to macrophage-stromal crosstalk in bone infection models.